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Abstract 
Background: Peptides have recently become attractive for therapeutic applications. However, efficient production of 
medium- to large-sized peptides (30–100 amino acids [aa]) remains challenging both by recombinant and chemical 
synthesis. We previously reported the formation of active enzyme aggregates in Escherichia coli cells induced by the 
short β-structured peptide ELK16 (LELELKLKLELELKLK) and developed a streamlined protein expression and purifica-
tion approach. In this approach, a cleavable self-aggregating tag (cSAT) consisting of an intein molecule and ELK16 
was used to release the recombinant peptides with reasonable purity from active aggregates.
Results: In this work, we extended the cSAT approach to a generalized expression and purification solution for a set 
of medium- to large-sized peptides with important therapeutic uses, including human glucagon-like peptide 1 (31 
aa), B-type natriuretic peptide (32 aa), exendin 4 (39 aa), chemokine (C–C motif ) ligand 5 (also known as RANTES, 66 
aa), stromal cell-derived factor 1α (67 aa), insulin-like growth factor 1 (70 aa), and leptin (146 aa). After intein-mediated 
cleavage, the soluble peptides were released directly into the supernatant while insoluble peptides could be refolded 
and purified by reverse phase high-performance liquid chromatography. Additionally, an N-terminal thioredoxin tag 
was added upstream of the target peptides, which can be removed by enterokinase cleavage, generating native 
N-terminus for target peptides. Final yields of the peptides ranged from 0.1 to 1.8 μg/mg wet cell weight at laboratory 
scale.
Conclusions: The approach described in this study provides a fast and efficient route to express and purify peptides 
that are difficult or expensive to produce by chemical synthesis or by ordinary recombinant methods. It is particularly 
well suited for large peptides, peptides likely to be degraded, and peptides that have toxic effects on the host. It can 
greatly reduce the cost and time of downstream processing, and thus may be useful for both industrial manufacture 
and laboratory applications.
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Background
Development of facile and efficient techniques for the 
production of proteins and peptides has always been an 
important goal of biotechnology. Proteins and peptides 
play a crucial role in the biopharmaceutical industry as 
therapeutics and diagnostics in a variety of treatments, 
including endocrine disorders, cancer, and infectious 
diseases [1, 2]. In recent years, interest in using pep-
tides as therapeutic agents has increased because of their 
high activity per unit mass, great chemical and biologi-
cal diversity, and low toxicity [3, 4]. Escherichia coli (E. 
coli) is a preferred choice for producing recombinant 
proteins and peptides under 30 kDa that do not require 
complex post-translational modifications. This is owing 
to its fast growth rate, high product yield, and ease of 
culture. Given its ease of use, approximately 30 % of the 
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recombinant products on the market are produced using 
E. coli [2, 5–7]. However, producing peptides shorter 
than 100 amino acids (aa) in E. coli is challenging because 
these peptides are susceptible to degradation [8–11]. In 
contrast, successful chemical synthesis and purifica-
tion of peptides longer than 30 aa is difficult and highly 
sequence dependent [12]. Given the potential therapeu-
tic value of peptides, an approach that enables efficient 
recombinant production of 30–100 aa peptides in E. coli 
could be immensely beneficial.
To overcome the difficulties associated with express-
ing foreign genes in E. coli, a diverse range of fusion tags 
has been developed that enhances stability and facili-
tates purification [13, 14]. One emerging class of fusion 
tags relevant to producing recombinant peptides results 
in the sequestration of fused peptides in inclusion bod-
ies, which confer resistance to degradation, high expres-
sion rates, and simple recovery [15]. These tags include 
the very hydrophobic bacterial ketosteroid isomerase 
(KSI) [16], the autoprotease Npro of classical swine fever 
virus [9, 17], and the elastin-like polypeptide (ELP) [18, 
19]. However, the above fusion tags are typically large 
(over 120 aa). Moreover, separation of the target peptide 
from the fusion tags may require harsh chemical cleavage 
methods (as for the KSI scheme), tedious refolding (as 
for the Npro scheme), or multiple phase transition cycling 
steps (as for the ELP scheme). Previously, we reported 
that C-terminal fusions of the short β-structured self-
assembling peptide ELK16 (LELELKLKLELELKLK) can 
induce the formation of highly active enzyme aggregates 
[20]. Based on this finding, we designed a streamlined 
protein expression and purification approach. Briefly, 
target proteins were fused at the N-terminus of a cleav-
able self-aggregating tag (cSAT) composed of an Mxe 
GyrA intein and ELK16. The fusion proteins assembled 
as insoluble aggregates, which were isolated by cen-
trifugation, where the self-cleavage activity of the intein 
was retained. After dithiothreitol (DTT)-induced intein 
cleavage, the target proteins were released into the solu-
ble fraction, where they could be easily separated from 
the remaining insoluble protein. This single-step purifica-
tion approach is capable of producing proteins with high 
yield and reasonable purity while reducing the cost and 
time required for purification [21].
In this study, we further extended the approach to 
successfully produce several therapeutically impor-
tant peptides with lengths ranging from 30 to over 100 
aa in E. coli cells, including the glucagon-like peptide 1 
(GLP-1, 31 aa) [22], B-type natriuretic peptide (BNP, 32 
aa) [23], exendin 4 (Ex-4, 39 aa) [24], chemokine (C–C 
motif ) ligand 5 (CCL5, also known as RANTES, 66 aa) 
[25], stromal cell-derived factor 1α (SDF-1α, 67 aa) [26], 
insulin-like growth factor 1 (IGF-1, 70 aa) [27], and 
leptin (146 aa) [28]. All these peptides are of human 
origin except for Ex4, which is from Heloderma suspec-
tum. Based on the expression and intein-mediated cleav-
age results, the above peptides were classified into three 
groups corresponding to different production schemes. 
After DTT induced intein-cleavage, the soluble peptides 
were released directly into the supernatant, as illustrated 
by GLP-1. For peptides that were insoluble after cleav-
age, another scheme involving further refolding steps was 
undertaken, by which CCL5, SDF-1α, IGF-1, and lep-
tin were successfully purified. Additionally, to facilitate 
with the peptide expression in prokaryotic E. coli cells 
and eliminate the N-terminal methionine residue, we 
incorporated the thioredoxin (Trx) encoded by the trxA 
gene of E. coli followed by an enterokinase cleavage site 
as N-terminal fusion tag to the target peptides [29, 30]. 
With the Trx fusion tag, GLP-1, SDF-1α, and the previ-
ously unexpressed BNP and Ex4 were all produced in 
sufficient amounts and released into the soluble fraction. 
Then, peptides with native N-terminus were generated 
by removing the Trx tag by enterokinase cleavage, veri-
fied by matrix-assisted laser desorption ionization mass 
spectrometry (MALDI-TOF MS) analyses. Final yields of 
the peptides ranged from 0.1 to 1.8 μg/mg wet cell weight 
at laboratory scale. The approach described here may be 
of particular interest for the recombinant production of 
medium- to large-sized peptides that are prone to prote-
olysis, toxic to the host, or in other aspects challenging to 
express in E. coli cells.
Results
Constructions of fusion proteins
Two sets of vectors were constructed in this study, as 
shown in Fig.  1a. The first vector, pET-P-Intein-ELK16, 
was used to express the fusion protein peptide-intein-
ELK16. It was based on a previously constructed vec-
tor pET30a-LipA-I-ELK16, where the intervening aa 
between the intein cleavage site and the target peptide 
C-terminus were removed [21]. The second vector, pET-
Trx-P-Intein-ELK16, was modified from the first vector 
by inserting Trx (12.5 kD) encoded by the trxA gene of 
E. coli together with an enterokinase cleavage site Asp–
Asp–Asp–Asp–Lys (D4K) upstream of the target peptide 
sequence. The scheme for producing recombinant pep-
tides with the second vector is illustrated in Fig. 1b. Trx is 
one of the most commonly used fusion tags for improv-
ing protein expression and enhancing solubility in E. coli 
[31, 32]. Despite its high solubilization capacity, Trx can 
be directed into insoluble aggregates by ELK16 and then 
released into the soluble fraction after intein cleavage, 
as shown in Fig.  1c. pET-Trx-P-Intein-ELK16 was con-
structed to express the fusion protein Trx-peptide-intein-
ELK16 to both improve the expression of peptides with 
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difficult N-terminal sequences and increase the solubility 
of more hydrophobic peptides. Afterwards, the Trx tag 
was removed by enterokinase cleavage, generating the 
authentic N-terminus for the target peptide.
Expression and intein‑mediated cleavage of fusion 
proteins
Seven model peptides with lengths between 31 and 147 
aa were used in this work, and the sequences are listed in 
Additional file 1. For the scheme lacking the N-terminal 
Trx fusion, the target peptides GLP-1, IGF-1α, CCL5, 
SDF-1α, and leptin accumulated approximately 28.4–
44.6 μg/mg wet cell weight as insoluble aggregates when 
fused to the self-cleavable intein-ELK16 tag (Fig.  2a; 
Table 1). The aggregates were then isolated by centrifuga-
tion and subjected to cleavage with 40 mM DTT at 4 °C 
for 24  h. GLP-1 was successfully released into the solu-
ble fraction, and the apparent molecular mass was con-
sistent with the theoretical value (3.5 kDa), indicating no 
degradation. The yield of purified GLP-1 was estimated 
to be 1.8 μg/mg wet cell weight, with 46.8  % recovery 
(Table 1). The purity was estimated to be 47 % with the 
residual fusion partner intein-ELK16 as the major impu-
rity. Afterwards, GLP-1 was purified to homogeneity by 
reverse phase-high performance liquid chromatography 
(RP-HPLC), with the final product yield estimated to be 
0.8 μg/mg wet cell weight, or 2.2 mg/L of OD600 2.0 LB 
culture (Scheme 1A in Table 2).
Fig. 1 Construction of expression vectors. a The first expression vector pET-P-Intein-ELK16 was based on the previously constructed vector pET30a-
LipA-I-ELK16. The second vector pET-Trx-P-Intein-ELK16 was derived from the first vector by inserting the thioredoxin (Trx) sequence followed by 
an enterokinase cleavage site Asp–Asp-Asp–Asp–Lys (D4K) upstream of the target peptide. b Schematic for producing recombinant peptides using 
vector pET-Trx-P-Intein-ELK16. c Expression and intein-mediated cleavage result of Trx. Lane IL, insoluble fraction of cell lysate after washing twice 
with buffer B1; lanes IC and SC, insoluble and soluble fraction of cleaved fusion protein
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However, for IGF-1, CCL5, SDF-1α, and leptin, most 
of the target peptide remained in the insoluble aggre-
gates after cleavage, with peptide yields between 3.5 and 
10.5 μg/mg wet cell weight and recoveries between 46.8 
and 62.0  % (Table  1). These insoluble peptides required 
subsequent refolding steps to be separated from the 
fusion partner intein-ELK16, as described in the fol-
lowing section. For peptides BNP and Ex-4, no obvious 
expression was detected, probably because the N-ter-
minal sequences of the two peptides were difficult to 
express in E. coli (data not shown).
For the scheme including the N-terminal Trx fusion 
(Fig. 1b), six target peptides, including GLP-1, the previ-
ously unexpressed BNP and Ex-4, and the insoluble IGF-
1, CCL5, and SDF-1α (please see above), were now all 
successfully expressed. Upon intein-mediated cleavage, 
for GLP-1, BNP, Ex4, and IGF-1α, the Trx fusion peptides 
were released mostly in the soluble fraction, with yields 
between 3.4 and 13.4  μg/mg wet cell weight (Fig.  2b; 
Table 1). The recovery ranged from 46.2 to 73.1 %, which 
was comparable to those without the Trx tag. However, 
for CCL5 and SDF-1α, only a small percentage of the 
cleaved Trx fusion peptides distributed in the soluble 
fraction. The yield was 7.0 and 5.0 μg/mg wet cell weight 
while the recovery decreased to 26.5 and 19.3 %, respec-
tively (Fig.  2b; Table  1). Leptin was still insoluble even 
with the N-terminal Trx tag and was not included in the 
following experiments (data not shown).
Fig. 2 Expression and intein-mediated cleavage of fusion proteins. 
a Expression of five target peptides using the peptide-intein-ELK16 
construct, designated with GLP1, IGF1, SDF1, CCL5, and Leptin. b 
Expression of six target peptides using the Trx-peptide-intein-ELK16 
construct, designated with T-Ex4, T-GLP1, T-BNP, T-SDF1, T-CCL5, and 
T-IGF1. Lane IL, insoluble fraction of cell lysate after washing twice 
with buffer B1; lanes IC and SC, insoluble and soluble fraction of 
cleaved fusion protein; lane PU, final product of target peptide after 
RP-HPLC purification; lanes 1, 2, and 3, quantification standards (Std) 
consisting of bovine serum albumin (BSA, 66.5 kDa) at 3, 1.5, and 
0.75 µg/lane and aprotinin (6.5 kDa) at 1. 5, 0.75, and 0.3 µg/lane 
respectively; lanes 4, 5, 6, and 7, quantification standards (Std) consist-
ing of bovine serum albumin (BSA, 66.5 kDa) at 6, 3, 1.5, and 0.75 µg/
lane, respectively. The molecular masses of the protein standards M1 
and M2 are listed by the left and right side separately
Table 1 Protein quantitation
a Yield of protein aggregate
b Yield of free target peptide after intein-mediated cleavage from LB culture with wet cell weight of 2.66 ± 0.99 mg/mL, estimated by densitometry analysis software 
Quantity One
c Cleavage efficiency as calculated by dividing the amount of cleaved protein aggregate over that of the total aggregate before cleavage
d Percent recovery in terms of mass as calculated by dividing the mass of the free peptide after cleavage over that could be theoretically obtained from the respective 
protein aggregate, assuming a complete cleavage and release
e The peptides were in the insoluble fraction after intein-mediated cleavage
Target peptide MW (kD) Aggregate yielda  
(μg/mg wet cell pellet)
Peptide yieldb  






 GLP-1 3.5 31.1 1.8 60.9 46.8
 IGF-1αe 7.8 35.4 5.2 70.6 62.0
 CCL5e 7.8 35.5 5.2 70.9 61.3
 SDF-1αe 8.0 28.4 3.5 53.3 50.7
 Leptine 16.2 44.6 10.5 60.3 60.3
pET-Trx-P-Intein-ELK16
 Trx-GLP-1 16.9 52.4 9.7 57.4 46.2
 Trx-IGF-1α 21.2 34.0 9.2 67.8 59.4
 Trx-CCL5 21.2 57.8 7.0 44.8 26.5
 Trx-SDF-1α 21.2 56.5 5.0 35.3 19.3
 Trx-BNP 17.0 49.9 13.4 67.1 66.6
 Trx-Ex-4 17.7 11.4 3.4 75.3 73.1
Page 5 of 9Zhao et al. Microb Cell Fact  (2016) 15:136 
Enterokinase cleavage of Trx‑peptide and purification 
of target peptides
For the target peptides that were expressed using the 
N-terminal Trx fusion, enterokinase cleavage was per-
formed to remove the sequence upstream of the Trx 
tag. After reaction with 0.001  % (w/w) enterokinase at 
23  °C for 16  h, almost 100  % of the Trx-peptide fusion 
proteins for GLP-1, BNP, Ex-4, CCL5, and SDF-1α were 
cleaved into two parts: the Trx tag and the target pep-
tides (Fig. 3a). For IGF-1, however, cleavage occurred at 
a non-canonical enterokinase site, leading to a truncated 
peptide (data not shown). Except for CCL5, which accu-
mulated in the insoluble fraction following enterokinase 
cleavage, the other four peptides remained soluble with-
out the Trx tag (Fig. 3a). The soluble target peptides were 
then separated from the Trx tag by RP-HPLC, as exem-
plified by GLP-1 purification (Fig. 3b). Final yields of the 
peptides ranged from 0.2 to 1.8  μg/mg wet cell weight, 
corresponding to 0.5–4.9  mg/L OD600 2.0  LB culture 
(Scheme 2 in Table 2). The collected samples were then 
subjected to analyses by MALDI-TOF MS (see Addi-
tional file  2). For comparison, the MS value of GLP-1 
expressed and purified by both methods was determined 
to be 3486.6/3355.0, consistent with the theoretical value 
of 3486.3/3355.1, which suggested correct processing by 
enterokinase (Fig. 3c).
Refolding and purification of insoluble target peptides
Refolding of the insoluble peptides IGF-1, CCL5, 
SDF-1α, and leptin was performed by unfolding the 
aggregates under chaotropic conditions (Buffer B1 with 
6 M guanidine hydrochloride) followed by rapid 50-fold 
dilution in refolding buffer (Buffer BR). The insoluble 
debris of the diluted sample was removed by centrifu-
gation and filtration, while the soluble fraction was then 
concentrated by ultrafiltration and subjected to SDS-
PAGE (Fig.  4). All four target peptides were solubilized 
under this condition. At the same time, the fusion part-
ner intein-ELK16 was also refolded and remained in the 
soluble fraction as the major impurity. The target pep-
tides were further purified to homogeneity by RP-HPLC, 
with the final yield of 0.1 to 0.6 μg/mg wet cell weight, 
corresponding to 0.3–1.6  mg/L OD600 2.0  LB culture 
(Scheme 1B in Table 2).
Discussion
In this work, we reported a generalized expression and 
purification solution for a set of medium- to large-sized 
peptides (between 30 and 150 aa) in E. coli cells based on 
a cleavable self-aggregating tag (cSAT) [20, 21]. The tar-
get peptides were produced and purified using three dif-
ferent schemes that accommodated a range of expression 
levels and hydrophobicity as summarized in Table 2. This 
approach features the efficient accumulation of a variety 
of target peptides into self-assembled aggregates and easy 
separation by intein-mediated cleavage, providing high 
expression rates and resistance to degradation.
The first scheme (Scheme  1A in Table  2) is especially 
advantageous for hydrophilic peptides that are prone to 
degradation when recombinantly expressed in E. coli, like 
GLP-1 in this study. GLP-1 is a gastrointestinal hormone 
with significant pharmaceutical importance in treating 
Table 2 Summary of peptide production and purification schemes
a Yield of target peptide after fine purification by RP-HPLC from LB culture with wet cell weight of 2.66 ± 0.99 mg/mL, quantified by the Pierce® bicinchoninic acid 
(BCA) assay kit
b The final recovery after RP-HPLC purification listed in parentheses and calculated by dividing the product peptide yield by the theoretical value from aggregate 
yield in Table 1
Target peptide Final yield of respective schemes (μg/mg wet cell pellet)a
Scheme 1A Scheme 1B Scheme 2
Step 1: Expression of fusion protein Peptide-
Intein-ELK16
Step 1: Expression of fusion protein Peptide-
Intein-ELK16
Step 1: Expression of fusion protein 
Trx-Peptide-Intein-ELK16
Step 2: Intein-mediated cleavage Step 2: Intein-mediated cleavage Step 2: Intein-mediated cleavage
Step 3: RP-HPLC Step 3: Refolding Step 3: Enterokinase cleavage
Step 4: RP-HPLC Step 4: RP-HPLC
GLP-1 0.8 (20.8 %)b – 1.1 (25.2 %)
BNP No expression – 1.8 (42.2 %)
Ex-4 No expression – 0.3 (26.5 %)
IGF-1α Insoluble 0.3 (3.6 %) Unwanted enterokinase site
CCL5 Insoluble 0.1 (1.2 %) Insoluble
SDF-1α Insoluble 0.4 (5.8 %) 0.2 (2.0 %)
Leptin Insoluble 0.6 (3.4 %) Insoluble
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type 2 diabetes and is rapidly degraded by proteolytic 
enzymes when expressed in E. coli without modifications 
[33]. Previous E. coli expression and purification strate-
gies for GLP-1 (using either a glutathione S-transferase 
(GST) or ubiquitin tag) require multiple processing and 
chromatography steps [33, 34]. In contrast, this strategy 
greatly simplified the expression and purification proce-
dure, yielding a comparable recovery relative to that of 
the original fusion protein (the GST strategy, 31.6 %; the 
ubiquitin strategy, 5.4 %; our study, 20.8 %) [33, 34].
For many therapeutic peptides, the native N-termi-
nus is essential and the initiator methionine must be 
removed. However, when recombinantly expressed in 
E. coli, the initiator methionine residue at the N-termi-
nus of the target peptide usually remains owing to inef-
ficient processing of the formyl-methionyl residue by 
Fig. 3 Production of target peptides with native N-terminus by removal of the Trx tag. a Enterokinase cleavage of Trx-peptide and purification 
results for different target peptides, designated with T-Ex4, T-GLP1, T-BNP, T-SDF1, and T-CCL5. Black arrow Trx; blue arrow target peptide. Lanes SC 
and EK, Trx-peptide before (soluble fraction of intein cleaved fusion protein) and after enterokinase cleavage; lane PE, precipitate after enterokinase 
cleavage of T-CCL5; lane PU, final product of target peptide after RP-HPLC purification; lanes 1, 2, and 3, quantification standards (Std) consisting of 
bovine serum albumin (BSA, 66.5 kDa) at 3, 1.5, and 0.75 µg/lane and aprotinin (6.5 kDa) at 1.5, 0.75, and 0.3 µg/lane, respectively. The molecular 
masses of the protein standards M1 and M2 are listed by the left and right side separately. b RP-HPLC separation of target peptide and Trx after 
enterokinase cleavage, illustrated by the chromatographic diagram of GLP-1. X axis retention time; Y axis peak height measured in mV. c MALDI-TOF 
analysis of GLP-1 produced using the vector pET-P-Intein-ELK16 (GLP1, left) or pET-Trx-P-Intein-ELK16 (T-GLP1, right)
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endogenous deformylases and aminopeptidases [35]. In 
the second scheme (Scheme 2 in Table 2), an additional 
N-terminal fusion tag Trx was incorporated that could 
be removed by enterokinase cleavage. Trx is one of the 
most common fusion tags for improving protein expres-
sion in E. coli and has been reported to enhance the cyto-
plasmic solubility of proteins with disulfide bonds [36]. 
While BNP and Ex4 were not able to be expressed when 
using the first scheme, the fusion proteins Trx-BNP and 
Trx-Ex4 were efficiently expressed and then released as 
soluble fractions after intein-mediated cleavage. All four 
peptides produced by the second scheme, including GLP-
1, BNP, Ex4, and SDF-1α, were obtained with correctly 
processed N-terminus, verified by MALDI-TOF MS 
analysis. Thus, the second scheme was very applicable 
to the target peptide that required a native sequence, or 
otherwise poorly expressed in E. coli.
However, some target peptides are prone to form 
aggregates and are unable to be released into the super-
natant after intein-mediated cleavage. Cleaved peptides 
may remain insoluble owing to exposure of hydropho-
bic sequences, or the difficulty of forming correct double 
disulfide bonds in the cytoplasmic space in E. coli, like 
CCL5 (2 disulfide bonds), SDF-1α (3 disulfide bonds), 
and leptin (1 disulfide bond) in this work. In this case, the 
third scheme (Scheme  1B in Table  2) can be employed, 
which involves denaturation and refolding. As illustrated 
by SDF1-α, we discovered previously that the E. coli 
strain BL21(DE3) harboring the plasmid pET30a with 
SDF1-α sequence inserted in the MCS failed to produce 
the target band on SDS-PAGE (data not shown) and the 
chemical synthesis of this peptide also failed because of 
the long length. In this study, SDF1-α was produced as an 
aggregate and purified by refolding and RP-HPLC, with a 
final yield of 0.4 μg/mg. The recovery rate for this scheme 
was generally low compared with previous reports that 
involved large-scale fermentation and refolding [37–39]. 
The largest loss was due to the ultrafiltration step used in 
our refolding process, which gave only 20–50 % recovery. 
Even so, the third scheme provides a proof-of-concept 
means for the production of these peptides.
Conclusions
Currently, downstream processing represents a major 
factor in terms of time and cost for the manufacturing of 
recombinant peptide or protein biopharmaceuticals. The 
approach we describe here provides a fast and efficient 
way to express and purify therapeutically important pep-
tides that are difficult or expensive to produce by chemi-
cal synthesis or by ordinary recombinant methods. It 
may have the potential for both laboratory research work 
and industrial manufacture. The cSAT strategy described 
in this study may also be applicable to other industrial 
strains other than E. coli.
Methods
Materials
The DNA sequences encoding BNP, GLP-1, EX4, SDF1-α, 
CCL5, IGF-1, and leptin were optimized for expression 
in E. coli and synthesized by Genscript (Nanjing, China). 
Oligonucleotides for cloning were synthesized by Inv-
itrogen (Shanghai, China). Restriction enzymes and 
DNA polymerases were purchased from New England 
Biolabs (Beverly, MA) or Takara (Dalian, China). The 
vector pET30a and strain E. coli BL21(DE3) were from 
Novagen (Madison, WI, USA). The kits for DNA purifi-
cation, gel recovery, and plasmid mini-preparation were 
obtained from Tiangen (Beijing, China). Sequencing was 
performed by Invitrogen or by SinoGenoMax (Beijing, 
China). All other chemicals were of analytic grade.
Construction of expression vectors
The target peptide sequence were inserted into the 
NdeI and SpeI sites of the previously constructed plas-
mid pET30a-LipA-I-ELK16, yielding the first expression 
vector pET-P-Intein-ELK16 [21]. For the second vec-
tor, the trxA gene (GenBank: AAA24534.1) encoding 
thioredoxin (Trx) was amplified from the E. coli BL21 
(DE3) genome, digested with NdeI and SpeI restriction 
enzymes, and then ligated with the similarly digested 
pET30a-LipA-I-ELK16. The resultant plasmid pET-Trx-
Intein-ELK16 contained a GS linker and an additional 
BglII site between the Trx and intein sequences. The tar-
get peptides were amplified with the introduction of an 
Fig. 4 Refolding and purification of insoluble peptides. The refolding 
and purification results of different peptides, designated with Leptin, 
CCL5, SDF1, and IGF1. Lane IC, insoluble fraction after intein-mediated 
cleavage; lane SR, soluble fraction after refolding of the insoluble 
peptides; lane PU, final product of target peptide after RP-HPLC 
purification; lanes 1, 2, and 3, quantification standards (Std) consisting 
of bovine serum albumin (BSA, 66.5 kDa) at 3, 1.5, and 0.75 µg/lane 
and aprotinin (6.5 kDa) at 1.5, 0.75, and 0.3 µg/lane, respectively. The 
molecular masses of the protein standards M1 and M2 are listed by 
the left and right side separately
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enterokinase site DDDDK at the 5′ end, digested with 
BglII and SpeI restriction enzymes and inserted into the 
digested pET-Trx-Intein-ELK16 with the same cohesive 
ends, yielding the second expression vector pET-Trx-P-
Intein-ELK16. E. coli BL21 (DE3) was used throughout 
for cloning and protein expression.
Expression and intein‑mediated cleavage of fusion 
proteins
Escherichia coli BL21(DE3) cells harboring plasmid pET-
P-Intein-ELK16 or pET-Trx-P-Intein-ELK16 were inocu-
lated into Luria–Bertani (LB) medium supplemented with 
50 mg/L kanamycin and incubated at 37 °C with shaking 
(250  rpm). Isopropyl β-D-1-thiogalactopyranoside was 
added to a final concentration of 0.2 mM to initiate pro-
tein expression when OD600 reached 0.4–0.6. The cul-
tures were then continued for an additional 6 h at 30  °C 
(for the peptide GLP-1 and Ex4, expression was carried 
out at 37 °C for 6 h to achieve better expression), and then 
harvested by centrifugation at 6000×g for 10 min and pel-
lets were stored at −70 °C for further assay and analysis.
Harvested cell pellets were re-suspended in buffer B1 
(20 mM Tris–HCl, 500 mM NaCl, 1 mM EDTA, pH 8.5) 
to 10 OD culture/mL, followed by sonication (Ultrasonic 
crasher; Scientz JY92-IIN, Ningbo, China). The soluble 
fractions were isolated from the aggregates by centrifuga-
tion at 15,000×g for 15 min at 4 °C. The precipitates were 
washed twice with buffer B1, and re-suspended in the 
same volume of Buffer B3 (20  mM Tris–HCl, 500  mM 
NaCl, 1  mM EDTA, 40  mM dithiothreitol, pH 8.5). 
Intein-mediated cleavage reactions were performed by 
incubating the samples at 4 °C overnight. Then, the solu-
ble and insoluble fractions were separated by centrifuga-
tion at 15,000×g for 15 min at 4 °C.
Protein quantification
Protein samples were analyzed by denaturing polyacryla-
mide gel electrophoresis using 12  % SDS-PAGE gels or 
precast NuPAGE® precast 4–12  % Bis–Tris Gels from 
Invitrogen (Beijing, China), followed by staining with 
Coomassie Brilliant Blue G-250. The compositions and 
protein amounts of all samples were determined densito-
metrically with Quantity One software (Bio-Rad Labora-
tories, Hercules, CA, USA) using bovine serum albumin 
(BSA) and aprotinin as standards and adjusted according 
to the loading volume.
Denaturation and refolding
The insoluble fraction after intein-mediated cleavage was 
re-suspended in Buffer BD (Buffer B1 containing 6  M 
guanidine hydrochloride) and incubated at 25 °C for 2 h. 
The insoluble debris was removed by centrifugation by 
centrifugation at 15,000×g for 15 min at 4 °C. Refolding 
was carried out by 1:50 dilution into Buffer BR (Buffer B1 
containing 0.1 mM reduced glutathione, and 0.1 mM oxi-
dized glutathione) with rapid stirring and then incubated 
at 4 °C for 24 h without further stirring. Insoluble debris 
containing unfolded proteins was removed by centrifu-
gation at 15,000×g for 15  min at 4  °C and then filtered 
through a 0.25-μm membrane. The soluble fraction was 
desalted and concentrated by ultrafiltration using a Mil-
lipore Amicon® Ultra-4 centrifugal filter device (3000 
molecular weight cutoff).
Reverse phase‑high performance liquid chromatography 
(RP‑HPLC)
The protein samples were applied to a BioBond™ C18 
or C4 column (250 × 4.6 mm) (Dikma, Tianjing, China) 
connected to a Prominence LC-20A HPLC system 
(Shimadzu, Hong Kong, China), and eluted using a lin-
ear gradient from 5 to 80  % mobile phase B (Phase A: 
0.12 % trifluoroacetic acid; Phase B: 80 % acetonitrile in 
water, 0.1 % trifluoroacetic acid) at a flow rate of 1 mL/
min over 60 min. Target peaks were collected using an 
automatic fraction collector FRC-10A (Shimadzu), lyo-
philized and resuspended in water for MALDI-TOF MS 
analysis.
Maldi‑tof ms
MALDI-TOF MS was performed using the linear mode 
on an ABI 4800 plus MALDI-TOF/TOF MS Spectrom-
eter by the Center of Biomedical Analysis, Tsinghua 
University.
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